Xoma: Why this Firm’s Upcoming Conference Call Is Very Important

Xoma’s (XOMA) webcast and conference call scheduled for September 15, 2016, at 1:30 p.m. PDT (4:30 p.m. EDT) is important and should be interesting to the firm’s shareholders. The conference call will provide an update on what’s going on in the Phase 2 trial of XOMA 358, the firm’s drug, which aims at treating congenital hyperinsulinism (CHI) and hypoglycemia post-bariatric surgery (PBS).
The Drug and the Diseases XOMA 358
The two conditions mentioned above are caused by abnormal

This content is for paid subscribers.
Please click here to subscribe or here to log in.